News | 2007
December 4, 2007
REPORT - Grand Rounds in Proteomics at the FDA
Renowned experts from industry and academia discussed the recent news and concepts in the field of clinical proteomics to train FDA reviewers on current applications for the future review of proteomic data.
December 1, 2007
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases
We evaluated the utility of SDS-PAGE/Western blot and CE coupled with MS (CE-MS) for detection of urinary polypeptide biomarkers of renal disease in patients with IgA-associated glomerulonephritides. In a reference cohort of 402 patients with various renal disorders and 207 healthy controls, we defined CE-MS patterns of renal damage and IgA nephropathy (IgAN) ...
November 9, 2007
Urine analysis enables cardiovascular risk assessment
Mosaiques diagnostics and an international network of renowned scientists from the British Heart Foundation (UK) and Baker Heart Research Institute (Australia) developed an innovative approach to distinguish between presence and absence of coronary artery disease by the straightforward analysis of urine.
View Press Release
October 31, 2007
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future
Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to further encourage interest in and discussion of clinically relevant biomarker research. We express our view on proteomics for biomarker discovery by addressing multiple relevant issues, including the inherent differences between biological fluids (and how these differences affect current analytical approaches) and experimental design to maximize the efficiency of moving from the bench to the bedside ...
August 17, 2007
Mass spectrometry based proteomics in urine biomarker discovery
All organisms contain 1,000s of proteins and peptides in their body fluids, which undergo disease-specific changes. Advances in the understanding of the functional relevance of these polypeptides under different (patho)physiological conditions and the identification of indicative changes with disease would greatly enhance diagnosis and therapy ...
August 10, 2007
Biomarkers for prostate cancer
Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa diagnosis. This article aims to provide concise information on the current findings that impact prostate cancer research …
July 20, 2007
Clinical Proteomics in Diabetes and Its Complications (National Institute of Health, Bethesda, MD, USA)
Prof. Dr. Dr. Harald Mischak: Scientific oral Presentation "Urinary Proteome Analysis Using Capillary Electrophoresis Coupled Mass Spectrometry for the Detection of Diabetes-Associated Pathologies"
July 10, 2007
Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases
IgA nephropathy is the most common primary glomerulonephritis and is a frequent cause for chronic kidney disease in children and young adults. Glomerular deposition of IgA also characterizes other renal disorders, including Henoch-Schoenlein purpura nephritis and immune-complex glomerulonephritis afflicting patients with liver disease due to chronic infection with the hepatitis C virus ...
July 10, 2007
High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine
All organisms contain thousands of proteins and peptides in their body fluids. A deeper insight into the functional relevance of these polypeptides under different physiological and pathophysiological conditions and the discovery of specific peptide biomarkers would greatly enhance diagnosis and therapy of specific diseases ...
June 8, 2007
Mosaiques diagnostics and Bayer HealthCare publish a novel proteomics-based approach for the evaluation of rat urine
An innovative procedure for analyzing rat urine provides novel insights into body fluids of animal models and enables the assessment of toxicological and physiological effects of pharmaceutical compounds in preclinical development.
June 5, 2007
Review on uraemic solutes II--variability in reported concentrations: causes and consequences
The aim of this manuscript is to initiate a constructive discussion about deviations in measured concentrations of uraemic solutes; these deviations, if not perceived or handled appropriately, may lead to incorrect interpretations of the pathophysiological role of uraemic solutes and/or to erroneous therapeutic decisions ...
May 1, 2007
CE - a multifunctional application for clinical diagnosis
CE has been used widely as an analytical tool with high separation power taking advantage of size, charge-to-size ratio, or isoelectric point of various analytes …
April 16, 2007
Mosaiques diagnostics GmbH and MHH investigators win cooperation award of the federal state of Lower Saxony
Urin test enables the early diagnosis of a life-threatening complication after stem cell transplantation.
View Press Release (German)
April 13, 2007
Grand Rounds in Proteomics at the FDA
A pilot process for biomarker qualification at the FDA should elucidate the potential of proteomic data for the drug development and evaluation process.
View Press Release
March 26, 2007
Improved safety for leukaemia patients after allogeneic hematopoietic stem cell transplantation
A perilous threat for hematopoietic stem cell recipients is the acute Graft-versus-Host Disease – The Hannover Medical School developed together with the mosaiques diagnostics & therapeutics AG an early diagnosis of this momentous disease.
View Press Release
March 5, 2007
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Acute graft-versus-host disease (aGvHD) contributes significantly to morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of GvHD is mainly based on clinical features and tissue biopsies. A noninvasive, unbiased laboratory test for GvHD diagnosis does not exist ...
January 22, 2007
Clinical proteomics: A need to define the field and to begin to set adequate standards
The aim of this manuscript is to initiate a constructive discussion about the definition of clinical proteomics, study requirements, pitfalls and (potential) use. Furthermore, we hope to stimulate proposals for the optimal use of future opportunities and seek unification of the approaches in clinical proteomic studies. We have outlined our collective views about the basic principles that should be considered in clinical proteomic studies, including sample selection, choice of technology and appropriate quality control, and the need for collaborative interdisciplinary efforts involving clinicians and scientists ...